Oncology Grand Rounds Series: Part 1 — Gastrointestinal Cancers

Video proceedings from the first in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Ms Jessica Mitchell, Dr Eileen M O’Reilly, Dr Philip A Philip and Ms Amanda Wagner. Introduction 0m0s Program overview: Dr Love Colorectal Cancer (CRC) (5:43) Case (Ms Wagner): A man in his mid-70s with metastatic appendiceal carcinoma who received third-line TAS-102 after disease progression on FOLFIRI/bevacizumab and FOLFOX/bevacizumab (8:11) Case (Ms Mitchell): A man in his early 40s with MSI-high metastatic CRC who experienced a dramatic response to pembrolizumab (29:59) Hepatocellular Carcinoma (HCC) (36:14) Case (Ms Wagner): A man in his mid-40s with metastatic HCC who developed hand-foot syndrome while receiving sorafenib (38:21) Case (Ms Mitchell): A woman in her mid-60s with metastatic HCC who had a good response to nivolumab but developed arthralgias (58:07) Pancreatic Cancer (1:04:33) Case (Ms Mitchell): A woman in her mid-70s with locally advanced pancreatic cancer who received neoadjuvant FOLFIRINOX (1:04:47) Case (Ms Wagner): A man in his mid-60s with metastatic pancreatic cancer who received nab paclitaxel/gemcitabine and nal-IRI (1:12:13) Gastroesophageal Cancers (1:20:20) Case (Ms Wagner): A man in his early 70s with metastatic esophageal adenocarcinoma who received FOLFOX followed by paclitaxel/ramucirumab upon disease progression (1:20:43) Case (Ms Mitchell): A woman in her early 60s with metastatic gastric cancer who experienced an excellent response to pembrolizumab but developed autoimmune hypothyroidism (1:24:02) Select publications